However, the growing list of known CF variants in conjunction with the increasing number of clinically approved CFTR modulators is fueling a rapid expansion in the potential number of variant-specific CF treatments (Fig. 5)—a long-term precision medicine problem (7). The gene discussed is CFTR; the disease is cystic fibrosis.